Transplant Research Division, University Health Network and Toronto General Hospital, Toronto, ON, Canada.
Department of Immunology Surgery, University of Toronto, Toronto, ON, Canada.
Immunology. 2018 Jul;154(3):465-475. doi: 10.1111/imm.12895. Epub 2018 Feb 20.
We previously showed that congenic bone marrow transplantation (BMTx) post myeloablation augmented tissue allograft survival in association with increased regulatory T (Treg) cells of both host and bone marrow donor origin. Regulatory B (Breg) cells can also modulate T-cell immunity and B cells may be implicated in the development of Treg cells. Accordingly, we explored the effect of B-cell depletion in vivo on augmented graft survival post BMTx. C57BL/6 mice received BALB/c skin allografts followed 7 days later by myeloablation using cyclophosphamide and busulphan. Mice then received T-cell-depleted bone marrow from CD45.1 congenic donors, and ongoing immunosuppression with rapamycin (to day 28 after BMTx). Control mice received cyclophosphamide and busulphan followed by rapamycin, but not congenic bone marrow. At different times post BMTx, mice received B-cell-depleting antibody treatment, and the effect on both skin graft survival, and induction of Treg cells was assessed. BMTx resulted in significantly prolonged skin graft survival versus control mice, in association with attenuated donor-specific alloreactivity relative to controls, increased splenic Treg cells and significantly diminished anti-donor IgG. In mice receiving infusion of B-depleting antibodies for 12 days from day 15 post BMTx, both graft survival and Treg cell activity were diminished, particularly for functional Treg cells of donor origin. Adoptive transfer of Breg cells from mice harvested at 15 days post BMTx prolonged survival in naive transplanted mice and increased Treg cell levels. Thus, autologous BMTx augmentation of graft survival is dependent in part upon a population of Breg cells that can modulate the function of donor-derived Treg cells.
我们之前的研究表明,骨髓移植(BMTx)后同种异体骨髓移植(BMTx)在增加供体和宿主来源的调节性 T(Treg)细胞的同时,增强了组织同种异体移植物的存活。调节性 B(Breg)细胞也可以调节 T 细胞免疫,B 细胞可能与 Treg 细胞的发育有关。因此,我们研究了体内 B 细胞耗竭对 BMTx 后移植物存活增强的影响。C57BL/6 小鼠接受 BALB/c 皮肤同种异体移植物,7 天后用环磷酰胺和白消安进行骨髓消融。然后,小鼠接受来自 CD45.1 同基因供体的 T 细胞耗尽的骨髓,并继续用雷帕霉素(BMTx 后第 28 天)进行免疫抑制。对照小鼠接受环磷酰胺和白消安,然后接受雷帕霉素,但不接受同基因骨髓。在 BMTx 后不同时间,小鼠接受 B 细胞耗竭抗体治疗,并评估其对皮肤移植物存活和 Treg 细胞诱导的影响。BMTx 导致皮肤移植物存活显著延长,与对照相比,同种异体反应性减弱,脾 Treg 细胞增加,抗供体 IgG 显著减少。在 BMTx 后第 15 天开始接受 B 细胞耗竭抗体输注 12 天的小鼠中,移植物存活和 Treg 细胞活性均降低,特别是供体来源的功能性 Treg 细胞。从 BMTx 后第 15 天收获的小鼠中过继转移 Breg 细胞可延长幼稚移植小鼠的存活时间,并增加 Treg 细胞水平。因此,自体 BMTx 增强移植物存活部分依赖于能够调节供体来源的 Treg 细胞功能的 Breg 细胞群。